First screen, captured .
Full page
Captured . Click for the whole screenshot.
Looks similar
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%(arstechnica.com)
136 points by _Microft | 25 comments
Ars Technica article reporting Phase 3 results showing Moderna and Merck's personalized mRNA melanoma vaccine with Keytruda cut recurrence or death risk by 42%.
Related stories
Mathematics of Geothermal Energy(ebsco.com)
67 points by srameshc | 37 comments
An EBSCO Research Starter article explaining how mathematical models are applied to geothermal energy, from geothermal gradients and reservoir flow to heat pumps and power plants.
First enhanced geothermal power plant completed in just 23 months(techcrunch.com)
137 points by hochmartinez | 59 comments
TechCrunch article reporting that the world's first enhanced geothermal power plant was completed in 23 months.
A startup doesn't need to be a unicorn(mattgiustwilliamson.substack.com)
538 points by MattSWilliamson | 324 comments
A Substack essay arguing that startups don't need to aim for unicorn-scale valuations; the page failed to load and showed an error message.
The Enterprise Experience(churchofturing.github.io)
458 points by Improvement | 130 comments
A personal blog post by a software developer reflecting snarkily on one year working at a large enterprise after a decade in startups and SMEs.
Nvidia's Risky Business(stratechery.com)
325 points by jonbaer | 157 comments
Stratechery article by Ben Thompson analyzing Nvidia's business risks, opening with a historical anecdote about financier Jay Cooke.
How a startup loses its spark(blog.johnqian.com)
451 points by imadj | 230 comments
A blog essay on why engineering work at small seed-stage startups feels intoxicating and how that spark fades as companies grow larger.